Abstract 16462: Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Among Non-Valvular Atrial Fibrillation Patients: A Propensity Score Matched Analysis of Four Large Databases

Steve Deitelzweig,Allison Keshishian,Xiaoyan Li,Melissa Hamilton,Cristina Masseria,Kiran Gupta,Xuemei Luo,Jack Mardekian,Keith Friend,Anagha Nadkarni,Xianying Pan,Gregory Y.H. Lip

Abstract 16462: Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Among Non-Valvular Atrial Fibrillation Patients: A Propensity Score Matched Analysis of Four Large Databases

2017

Steve Deitelzweig
Allison Keshishian
Xiaoyan Li
Melissa Hamilton
Cristina Masseria
Kiran Gupta
Xuemei Luo
Jack Mardekian
Keith Friend
Anagha Nadkarni
Xianying Pan
Gregory Y.H. Lip

Introduction: Clinical trials have shown that apixaban, dabigatran, and rivaroxaban were associated with similar to lower risks of stroke/systemic embolism (S/SE) and major bleeding (MB) compared t...

Keywords:

Dabigatran
Clinical trial
Apixaban
Internal medicine
Rivaroxaban
Cardiology
Medicine
Stroke
Propensity score matching
Diabetes mellitus
Atrial fibrillation

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations